Summary:
To evaluate the efficacy of an infusion of 100mg of eptinezumab vs. placebo administered during an acute attack of migraine in subjects with episodic migraine for headache pain freedom and absense of the most bothersome migraine-associated symptom (MBS) at 2-hours post completion of infusion.
Qualified Participants Must:
• Be at least 18 years of age
•
Experience between 4-14 migraines per month over the past 3 months
•
Be willing and able to come to the clinic during a migraine attack
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Study provided procedures such as blood work and EKG
- Physical with a board certified physician